Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Progesterone PopPK study combines machine-learning screening with conventional covariate modeling

Academic source · European Journal of Drug Metabolism and Pharmacokinetics

Source published: · Event / reporting date: 2026-11-06

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What the paper reports

A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.

Why this paper is included

Analysis: The workflow may inform efficient covariate screening, but statistical selection should remain distinct from clinically meaningful dose-adjustment decisions and prospective validation.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Related updates

Cleveland Clinic

Lp(a)HORIZON reports neutral cardiovascular outcomes despite substantial pelacarsen biomarker reduction

Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.

PharmaIN Corporation

PharmaIN reports Phase 1 multiple-dose PHIN-214 findings in cirrhosis

On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.

Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗